A PPARα (peroxisome proliferation activation receptor α) agonist (GW7647) activates nitric oxide synthase 1 (NOS1) to produce NO leading to cGMP accumulation in antral mucous cells. In this study, we examined how PPARα activates NOS1. The NO production stimulated by GW7647 was suppressed by inhibitors of PI3K (wortmannin) and Akt (AKT 1/2 Kinase Inhibitor, AKT-inh), although it was also suppressed by the inhibitors of PPARα (GW6471) and NOS1 (N-PLA). GW7647 enhanced the ACh (acetylcholine)-stimulated exocytosis (Ca 2+ -regulated exocytosis) mediated via NO, which was abolished by GW6471, N-PLA, wortmannin, and AKT-inh. The Western blotting revealed that GW7647 phosphorylates NOS1 via phosphorylation of PI3K/Akt in antral mucous cells. The immunofluorescence examinations demonstrated that PPARα existing with NOS1 co-localizes with PI3K and Akt in the cytoplasm of antral mucous cells. ACh alone and AACOCF 3 , an analogue of arachidonic acid (AA), induced the NOS1 phosphorylation via PI3K/Akt to produce NO, which was inhibited by GW6471. Since AA is a natural ligand for PPARα, ACh stimulates PPARα probably via AA. In conclusion, PPARα activates NOS1 via PI3K/Akt phosphorylation to produce NO in antral mucous cells during ACh stimulation.
Nitric oxide (NO) is an intracellular or intercellular messenger in many tissues, including gastric mucosa (1) . In gastric mucosa, NO, which is an important factor protecting gastric mucosa from the acid-peptic injury, increases mucin secretion and mucous gel thickness (2) (3) (4) . Mucins (high-molecular-weight glycoproteins) synthesized are stored in the intracellular granules and secreted into the lumen by the exocytosis in gastric mucous cells including antral mucous cells.
In antral mucous cells, the Ca 2+ -regulated exocytosis which is activated by ACh (acetylcholine) is the main mechanism for mucin release (8, 14, 15, 19) and is modulated by many substances, such as cAMP, NO, cGMP, intracellular Cl − , and arachidonic acid (AA) (8, 14, 19, (21) (22) (23) (24) . NO is synthesized by nitric oxide synthase 1 (NOS1) and enhances the Ca 2+ -regulated exocytosis mediated via cGMP accumulation in antral mucous cells (28) . Previous studies demonstrated that cGMP increases the releasable pool of mucous granules by accelerating the ATP-dependent priming leading to the enhancement of Ca 2+ -regulated exocytosis in antral mucous cells (11, 19) . Peroxisome proliferation activation receptor α (PPARα), the natural ligands of which are fatty acids including AA, enhances the Ca 2+ -regulated exocytosis in antral mucous cells (21, 28) . Our previous study (4-cyclohexylbutyl)amino]ethyl]phenyl]thio]-2-methylpropanoic acid (GW7647, a PPARα agonist), and N 5 -[Imino(propylamino)methyl]-L-ornithine hydrochloride (N-PLA, a NOS1 inhibitor) from Tocris (Bristol, UK). All reagents were dissolved in dimethyl sulfoxide (DMSO) and were diluted to their final concentrations immediately before the experiments. The final DMSO concentration did not exceed 0.1%, and this concentration had no effect on cell volume, intracellular Ca 2+ concentration ([Ca 2+ ] i ), intracellular Cl − concentration, and the exocytotic events in antral mucous cells (8, 9, 14, 15, 19, 21-24, 27, 28) .
Cell preparations. Hartley strain male guinea pigs (6 weeks of age) were purchased from SLC Inc. (Shizuoka, Japan) and fed standard pellet food and water. Guinea pigs were sacrificed by intraperitoneal injection of pentobarbital sodium (100 mg/kg), and then, the stomach was removed from the animal. The procedures for the cell preparation have been previously described (8, 9, 14, 15, 19, (22) (23) (24) . Briefly, the gastric antrum was excised from the stomach, and the mucosal layer was stripped from the muscle layer in cold phosphate buffered saline (4°C) using glass slides. The stripped antral mucosa was suspended in solution I containing 4% BSA (4°C) and then incubated in solution I containing 0.1% collagenase and 4% BSA for 12 min at 37°C. The digested mucosa was filtered through nylon mesh with a pore size of 300 μm square and washed three times. The cells were suspended in solution I containing 4% BSA (4°C). The cell suspension was stored at 4°C and used in experiments within 3 h. The procedures and protocols for these experiments were reviewed and approved by the Animal Research Committee of Kyoto Prefectural University of Medicine and by the Experimental Animal Research Committee of Osaka University of Pharmaceutical Sciences. The experiments were carried out in accordance with the Guidelines of these Committees.
Observation of exocytosis. The isolated antral tubular shaped glands were mounted on a coverslip pre-coated with neutralized Cell-Tak (Becton Dickinson Labware, Bedford, MA, USA) for firm attachment of the cells. The coverslip with the cells was set in a perfusion chamber mounted on the stage of a differential interference contrast microscope (BX50Wi; Olympus, Tokyo, Japan), which was connected to a videoenhanced contrast system (ARGUS-20; Hamamatsu Photonics, Hamamatsu, Japan) (8, 9, 14, 15, 19, (22) (23) (24) . Images were recorded continuously using a video recorder. The experiments were carried out at demonstrated that PPARα stimulates NOS1 to produce NO in antral mucous cells (28) . However, it remained uncertain how PPARα activates NOS1 in antral mucous cells. PPARα agonists have been shown to stimulate the NOS3 phosphorylation mediated via the phosphatidylinositol 3-kinase (PI3K)/ serine-threonine kinase (Akt) signal in endothelial cells (5, 16, 30) . In myocardium and endothelial cells, there are reports showing that PPARγ stimulates NO synthesis via the PI3K/Akt signal (18) . Based on these observations, we examined the effects of inhibitors of PI3K and Akt on the NO production stimulated by PPARα agonist (GW7647) plus ACh in antral mucous cells. In the course of experiments, we found that the inhibitors of PI3K and Akt abolished the enhancement of Ca 2+ -regulated exocytotic events stimulated by GW7647 plus ACh (Tanaka unpublished observation). Our previous report have shown that the inhibitors of NOS1 and PKG also inhibited the enhancement of Ca 2+ -regulated exocytotic events stimulated by GW7647 plus ACh (27, 28) . Thus, PPARα agonist may phosphorylate NOS1 mediated via PI3K/Akt to produce NO in antral mucous cells.
In this study, we examined the effects of PPARα agonists on the phosphorylation of PI3K, Akt, and NOS1 and on the NO release in the antral mucosa. We also examined the effects of PI3K inhibitor and Akt inhibitor on Ca 2+ -regulated exocytosis stimulated by the PPARα agonist plus ACh in antral mucous cells. The aim of this study is to confirm that PPARα activation stimulates NO production via NOS1 phosphorylation and is essential for maintaining Ca 2+regulated exocytosis in antral mucous cells. After the experiments, the antral mucosa remained was transferred immediately to a microtube, frozen in the liquid nitrogen and stored at −80°C until the Western blotting. The procedures for protein extraction and Western blotting have already been described in details (27, 28) . The antibodies used were an anti-NOS1 antibody (LS-B3272; LifeSpan BioSciences, WA, USA), an anti-PI3K antibody (No. #4257; Cell Signaling Technology, MA, USA), an anti-Akt antibody (No. #9272; Cell Signaling), an anti-phospho-NOS1 antibody (ADI-KAP-NO032; Enzo Life Sciences, NY, USA), an anti-phospho-PI3K antibody (GTX50858; Gene Tex, CA, USA), and an antiphospho-Akt (Ser473) antibody (No. #9271; Cell Signaling Technology). The protein band was visualized using an enhanced chemiluminescence reagent (EzWestLumi or EzWestLumi plus; ATTO CORPO-RATION, Tokyo, Japan) and captured using a Lumino-image analyzer (LAS 3000; Fuji Film Co., Tokyo, Japan). The band of each phosphorylated protein was normalized by that of β-actin as an internal control, and the phosphorylation levels of PI3K, Akt (Ser473), and NOS1 were expressed by normalized values. The "n" showed the number of animals.
MATERIALS AND METHODS

Solutions and chemicals. Solution
Immunofluorescence examination. The isolated antral tubular shaped glands attached on the coverslip were fixed in 4% paraformaldehyde for 30 min and dried. After the fixation, samples were stained for the immunofluorescence imaging using antibodies for PI3K (monoclonal rabbit, 1 : 200; Cell Signaling Technology), for Akt (polyclonal rabbit, 1 : 200; Cell Signaling Technology), and for PPARα (monoclonal mouse, 1 : 200; LifeSpan BioSciences). Samples were incubated with the antibodies for overnight (4°C), and then, with Alexa Fluor 488 (1 : 500; Invitrogen, Carlsbad, CA, USA) and Alexa Fluor 546 (1 : 500; Invitrogen) for 2 h. The samples on the coverslip were enclosed with VECTASHIELD HardSet Antifade Mounting Medium containing DAPI. Finally, the immunofluorescence images of antral mucous cells for PI3K, Akt, PPARα and DAPI were observed using a confocal laser scanning microscope, LSM 510META (Carl Zeiss, Jena, Germany).
Statistical analysis.
To compare the frequencies of initial phase among the different experiments, the statistical difference between the means was assessed using Student's t tests. To confirm increases of the late phase in an experiment, the frequencies (3.5-7 min from the start of ACh stimulation) were compared with the frequency just before the start of the transient increase in the late phase (3 min from the 37°C. The volume of perfusion chamber was approximately 20 μL, and the rate of perfusion was 200 μL/min. Exocytotic events, which were detected by rapid changes in the light intensity of the granules (8, 9, 14, 15, 19, (22) (23) (24) , were counted in two to four cells every 30 s and were normalized to the number of cells (events/cell/30s). The frequency of exocytotic events measured using six to eleven coverslips from two or three animals was expressed as the mean ± SE based on the number of experiments. In the statistical comparisons of the experiments, the frequencies of initial and late phases were used. The frequency at 1 min from the start of ACh stimulation was used as the frequency of the initial phase and that at 4 min from the start of ACh stimulation was the frequency of the late phase. In the experiments using GW6471, wortmannin, or AKT-inh, the highest frequency within 4-5 min from the start of ACh stimulation was used as the frequency of the late phase.
Measurements of NO released and Western blotting.
The stripped antral mucosa from an animal was cut into three pieces and stored at 4°C until the experiment. Before the start of experiment, the antral mucosa was incubated for 10 min in solution I (5 mL) aerated with 95% O 2 and 5% CO 2 at 37°C. In the control experiment, antral mucosa was incubated with the vehicle control (DMSO) for an additional 10 min. In the test experiments, antral mucosae were stimulated with ACh, GW7647, GW7647 plus ACh, AACOCF 3 , and AACOCF 3 plus ACh for an additional 10 min. In the experiments of inhibitors for PPARα (GW6471), PI3K (wortmannin), and Akt (AKT-inh), the antral mucosae were incubated with the inhibitors for 10 min, and then, they were incubated with the drugs including the vehicle control for an additional 10 min. The incubation solution (500 μL) was sampled before and after 10-min incubation with drugs. The solution sampled was immediately transferred to a microtube and cooled on ice. After experiments, the solution in the microtube was frozen in the liquid nitrogen and then stored at −30°C until the NO assay. The NO concentration of the sample was measured using a nitrate/nitrite fluorometric assay kit (No. 780051; Cayman Chemical Company, Ann Arbor, MI, USA). The amount of NO released for 10min was calculated from the difference between concentration of the incubation solution sampled before and 10 min after the addition of drugs, and expressed as nmol/g-wet tissue weight. The "n" showed the number of animals. and P-Akt (Ser473). The band densities of P-PI3K, P-Akt (Ser473), and P-NOS1 were normalized by the β-actin band, and the agonists significantly increased the normalized densities, as shown in Fig. 3C (P-PI3K), 3D (P-Akt (Ser473)), and 3E (P-NOS1). In the next experiments, antral mucosae were treated with GW6471 prior to the addition of the vehicle control or the agonists ( Fig. 3B : GW6471 experiments). In the presence of GW6471, the bands of P-PI3K, P-Akt (Ser473), and P-NOS1 were detected in the vehicle control experiment, but they were not enhanced by the agonists as shown in Fig. 3C (P-PI3K), 3D (P-Akt (Ser473)), and 3E (P-NOS1). Thus, GW6471 abolished the agonist-stimulated enhancements of phosphorylation in NOS1, PI3K, and Akt (Ser473). Experiments were carried out using wortmannin, instead of GW6471 ( Fig. 4A : Wortmannin experiments). In the presence of wortmannin, the bands of P-Akt (Ser473) and P-NOS1 were detected in the vehicle control experiment, and were not enhanced by the agonists, as shown in Fig. 4A . The normalized densities of P-Akt (Ser473) and P-NOS1 did not increase during stimulation with the agonists in start of ACh stimulation). Statistical significances were assessed by ANOVA. The statistical analysis for Western blotting or the amount of NO released was assessed using Student's t test. Differences were considered significant at P < 0.05.
RESULTS
The ACh concentration used for stimulation was 1 μM throughout the experiments. To activate PPARα of antral mucous cells, we used five kinds of agonist (ACh, GW7647, GW7647 plus ACh, AACOCF 3 , and AACOCF 3 plus ACh).
NO release
The addition of the agonists increased the amounts of NO released from the stripped antral mucosa (Fig. 1 ). The amounts of NO released (nmol/g-tissue) were 4.88 ± 0.17 with ACh (n = 3), 5.45 ± 0.86 with GW7647 (n = 3), 9.33 ± 2.71 with GW7647 plus ACh (n = 3), 8.10 ± 0.83 with AACOCF 3 (n = 4), and 11.68 ± 2.34 with AACOCF 3 plus ACh (n = 3), while it was 0.31 ± 0.04 nmol/g-tissue (n = 3) with the vehicle control (DMSO) ( Fig. 1) . Antral mucosae were also treated with wortmannin (50 nM, an inhibitor of PI3K) and AKT-inh (100 nM, an inhibitor of Akt) prior to the addition of the agonists. In the presence of wortmannin or AKTinh, the addition of the agonists did not induce any increase in the amounts of NO released from the stripped antral mucosa ( Fig. 1) . Moreover, the prior treatment of GW6471 (5 μM, an inhibitor of PPARα) or N-PLA (1 μM, an inhibitor of NOS1) also inhibited the increases in the amounts of NO released during stimulation with the agonists (28) . Thus, wortmannin and AKT-inh inhibited the NO release stimulated by the agonists in antral mucosa, similarly to GW6471 and N-PLA.
Phosphorylation of PI3K, Akt, and NOS1 stimulated by PPARα in antral mucosa
In the Western blotting, NOS1 and its phosphorylated form, the molecular mass of which is ~160 kDa, exist in antral mucosa and guinea pig brain. Similar results were reported in rat kidney and brain (26) . PI3K (~85 kDa), Akt (~60 kDa), and their phosphorylated forms exist in antral mucosa and MKN28 cells (a cell line of human gastric cancer) (Fig. 2) . The effects of the agonists on the bands of P-NOS1, P-PI3K, and P-Akt (Ser473) were examined. The addition of the agonists enhanced the P-NOS1 bands, compared with that of the vehicle control (Fig. 3A) , and also enhanced the bands of P-PI3K Experiments were also carried out using an AKTinh, instead of wortmannin ( Fig. 4D : AKT-inh experiments). In the presence of AKT-inh, the bands of P-PI3K and P-NOS1 were detected in the vehicle control experiment, and the bands of P-PI3K were enhanced by the agonists, but not those of P-NOS1 (Fig. 4D ). The normalized densities were plotted in Figs. 4E & F. The agonists increased the band densities of P-PI3K ( Fig. 4E ), but not those of P-NOS1 ( Fig. 4F) . Thus, in the antral mucosa, GW7647 stimulates the PI3K phosphorylation followed by the Akt (Ser473) phosphorylation, which induces NOS1 phosphorylation. Similar results were obtained by ACh alone and AACOCF 3 .
Localization of PI3K, Akt, and PPARα in antral mucous cells
Our previous study demonstrated that NOS1 and PPARα co-localize in the cytoplasm of antral mucous cells (28) . In the present study, we examined the localization of PI3K/PPARα (Figs. 5C-F) and Akt/PPARα (Figs. 5G-J) in the antral mucous cells. The antral mucous cells (the DIC microscopic image of living antral tubular gland ( Fig. 5A ) and that of fixed antral tubular gland by 4% paraformaldehyde (Fig. 5B) ), the cytoplasm of which was densely packed with mucous granules, lined along the tubular column. Antral mucous cells were positively stained for PI3K ( Fig. 5C ), Akt (Fig. 5G Fig. 5F , which merged Figs. 5C-E, showed that PI3K and PPARα co-localize in the cytoplasm of the antral mucous cells. Moreover, Fig. 5J , which merged Figs. 5G-I, also showed that Akt and PPARα co-localize in the cytoplasm of the antral mucous cells. In the Western blotting, the NOS1-, PI3K-, and Akt-band were detected in guinea pig antral mucosa (Figs. 2A, C, & E), and the PPARαband was also detected in guinea pig antral mucosa (21) . Guinea pig brain was used as the positive control for NOS1, and human cell line (MKN28) was used as the positive control for PI3K or Akt. The anti-Akt antibody used has been shown to have the cross-reactivity for guinea pig (data sheet supplied form Cell Signaling Technology). Based on these observation, the antibodies used in this study can be applicable for the immunofluorescence examinations in guinea pig antral mucous cells.
Effects of wortmannin and AKT-inh on ACh-stimulated exocytotic events modulated by PPARα
We examined the effects of wortmannin and AKT-inh on the Ca 2+ -regulated exocytotic events stimulated by Ser473)). NOS1(~160 kDa) (A) and P-NOS1 (B) exist in antral mucosa and guinea pig brain. PI3K (~85 kDa) (C) and P-PI3K (D) exist in antral mucosa and MKN28 cells. Akt (~60 kDa) (E) and P-Akt (Ser473) (F) exist in antral mucosa and MKN28 cells. The bands of NOS1, PI3K, Akt, and their phosphorylated forms (P-NOS1, P-PI3K, P-Akt (Ser473)) were detected in the antral mucosae.
or addition of GW7647 (50 nM) enhanced the initial phase of Ca 2+ -regulated exocytotic events stimulated by ACh in antral mucous cells, although the addition of GW7647 alone did not evoke any exocytotic event (Fig. 6A ). The frequencies of ACh-stimulated initial phase and late phase were 18.9 ± 0.9 and 2.9 ± 0.5 events/cell/30s (n = 7), respectively. This enhancement of the initial phase stimulated by GW7647 plus ACh was abolished by GW6471. The frequency of initial phase was 8.2 ± 1.4 events/cell/30s (n = 11). GW6471 caused the frequency of initial phase stimulated by GW7647 plus ACh to decrease to 73% of that stimulated by ACh alone, suggesting that ACh alone activates PPARα (Fig. 6A ). However, GW6471
ACh. The Ca 2+ -regulated exocytotic events is characterized by an initial peak in exocytotic events that declined rapidly (initial phase) followed by a second slower decline (late phase) lasting during ACh stimulation (8, 9, 14, 19, (21) (22) (23) (24) . In a previous study (28) , an increase in NO/cGMP stimulated by PPARα enhanced the initial phase of Ca 2+ -regulated exocytotic events in antral mucous cells and a NOS1 inhibitor (N-PLA) or a PKG inhibitor (Rp8BrPETcGMPS) abolished the enhancement of the initial phase and produced the delayed, but transient, increase in the late phase (27, 28) .
The similar experiments were carried out using GW7647, GW6471, and ACh in this study. The pri- in the late phase was also evoked by N-PLA or Rp8BrPETcGMPS (a PKG inhibitor). This indicates that the inhibition of NO synthesis inhibits cGMPdependent PDE2 (27, 28) . We examined the effects of wortmannin (50 nM) and AKT-inh (100 nM) on the exocytotic events stimulated by GW7647 plus ACh in antral mucous cells. IC 50 s of wortmannin and AKT-inh are 5 nM and 58 nM, respectively (Data sheets supplied from Wako). The prior addition of wortmannin abolished the enhancement of Ca 2+ -regulated exocytotic events stimulated by GW7647 plus ACh and produced the delayed, but transient, increase in the late phase (Fig. 6B) . The frequencies of initial phase and late produced a delayed, but transient, increase in the late phase stimulated by GW7647 plus ACh (4.5 ± 0.7 events/cell/30s, n = 11). A previous study demonstrated that antral mucous cells have cGMP-dependent PDE2 and the PDE2 inhibited by BAY60-7550 (a selective inhibitor of PDE2) produces the delayed, but transient, increase in the late phase (27) . BAY60-7550 induced cAMP accumulation and the delayed, but transient, increase in the late phase was abolished by PKI-amide (1 μM, a PKA inhibitor). Thus, the delayed, but transient, increase in the late phase was evoked by cAMP accumulation, which was induced by PDE2 inhibition (27, 28) . The delayed, but transient, increase GW7647 plus ACh and produced the delayed, but transient, increase in the late phase (Fig. 6C) . The frequencies of initial phase and late phase were 8.0 ± 0.3 and 4.4 ± 0.3 events/cell/30s (n = 6), respectively. Thus, in the Ca 2+ -regulated exocytotic events stimu-phase were 8.2 ± 0.4 and 4.5 ± 0.3 events/cell/30s (n = 6), respectively. Experiments were also carried out using AKT-inh, instead of wortmannin. The prior addition of AKT-inh also abolished the enhancement of Ca 2+ -regulated exocytotic events stimulated by lated by GW7647 plus ACh, wortmannin and AKTinh abolished the enhancement of initial phase and produced the delayed, but transient, increase in the late phase in antral mucous cells. The experiments in the Ca 2+ -regulated exocytosis indicate that the PPARα activates NOS1 mediated via the PI3K/Akt signal to produce NO in antral mucous cells.
DISCUSSION
This study demonstrates that the PPARα agonist stimulates NOS1 phosphorylation to produce NO in Fig. 6 Effects of PPARα on the Ca 2+ -regulated exocytotic events stimulated by ACh. ACh (1 μM) increased the frequency of exocytotic events in antral mucous cells: an initial phase followed by a late phase. A: Effects of GW7647 (an agonist of PPARα) and GW6471 (an antagonist of PPARα) on the exocytotic events stimulated by ACh. GW7647 (50 nM) enhanced the ACh-stimulated initial phase. GW6471 (5 μM) abolished the enhancement of initial phase and produced a delayed, but transient, increase in the late phase stimulated by GW7647 plus ACh. B: Effects of wortmannin on the exocytotic events stimulated by GW7647 plus ACh. Wortmannin (50 nM) abolished the enhancement of initial phase and produced a delayed, but transient, increase in the late phase stimulated by GW7647 plus ACh. C: Effects of AKT 1/2 Kinase Inhibitor (AKT-inh) on the exocytotic events stimulated by GW7647 plus ACh. AKT-inh (100 nM) abolished the enhancement of initial phase and produced a delayed, but transient, increase in the late phase stimulated by GW7647 plus ACh. *Significantly different from the corresponding values and ‡ significantly different from the value at 3 min ( Fig. 6A ), 3.5 min (Fig. 6B ) or 3 min (Fig. 6C ) from the start of ACh stimulation, respectively (P < 0.05).
antral mucous cells and suggests that the activation of PPARα is a key factor to produce NO in antral mucous cells. An inhibitor of PI3K (wortmannin) or of Akt (AKT-inh) did not induce any increase in NO release and any enhancement in NOS1 phosphorylation activated by PPARα agonists. Moreover, the PPARα agonists enhanced PI3K phosphorylation and Akt (Ser473) phosphorylation, and their enhancements were abolished by GW6471 in antral mucosa. Wortmannin inhibited the enhancement of Akt (Ser473) phosphorylation, but AKT-inh did not inhibit that of PI3K phosphorylation, indicating that Akt is a downstream signal of PI3K in the PPARα signal pathway in antral mucous cells. Immunofluorescence examinations demonstrated that PPARα co-localizes with PI3K and Akt in the cytoplasm of antral mucous cells, and PPARα and NOS1 also co-localize in the cytoplasm of antral mucous cells (28) . The PPARα ligands have been shown to phosphorylate PI3K/Akt in the endothelial cells (16, 30) . Thus, the activation of PPARα induces NOS1 phosphorylation mediated via the PI3K/Akt signal to produce NO in antral mucous cells. This study also demonstrated that NO produced by the PPARα activation plays an essential role for maintaining the Ca 2+ -regulated exocytosis in antral mucous cells. The NO-induced enhancement of Ca 2+ -regulated exocytosis is mediated by cGMP accumulation (28) . The antral mucous cells have cGMP-dependent PDE2, which degrades cAMP (27) . Therefore, the inhibition of NO synthesis resulting in no accumulation of cGMP evokes two characteristic responses in the Ca 2+ -regulated exocytotic events; abolishing the enhancement of initial phase and producing the delayed, but transient, increase in the late phase (27) . Inhibition of PPARα, NOS1, PI3K, and Akt also evoked the two characteristic responses in the Ca 2+regulated exocytotic events of antral mucous cells, supporting our previous observations that PPARα stimulates NO production via NOS1. On the other hand, we observed phosphorylation of PI3K and Akt even in the PPARα-unstimulated antral mucous cells, the level of which was lower than that in the PPARα-stimulated cells. The PI3K/ Akt signal is activated by many substances in addition to ACh or PPARα agonists, such as insulin, vascular endothelial growth factor, and other growth factors (10, 20, 25) . In antral mucous cells, these substances may stimulate the phosphorylation of PI3K/ Akt without ACh or PPARα agonists. The phosphorylation of PI3K/Akt under the PPARα-unstimulated condition appear to play a role in maintaining the basal functions of antral mucous cells, such as mucin synthesis, growth, and ion transport etc. Akt has two phosphorylation sites, Ser473 and Thr308 (17, 20, 25, 31) . The Western blotting of this study has demonstrated that Akt is phosphorylated at Ser473 under the basal condition, and PPARα agonists (ACh, GW7647, and AACOCF 3 ) enhance the phosphorylation of Akt at Ser473 as shown in Fig. 3 . Akt is also phosphorylated at Thr308 under the basal condition, but it was not enhanced by the PPARα agonists (data not shown). The phosphorylation of Akt at Thr308 is necessary for Akt activation, and the phosphorylation at Ser473 is required for the maximal activation (5, 6) . Thus, the activation of NOS1 requires the maximal activation of Akt, while the basal phosphorylation level at Thr308 is large enough for NOS1 activation.
There are reports showing that NOS1 and NOS3 play roles for mucosal protection (29) . The previous study demonstrated that NOS1 and NOS3 exist in antral mucosa. In immunohistochemical examinations, antral mucous cells were positively stained for NOS1, but the staining for NOS3 was faint (28) . Moreover, in antral mucous cells, an inhibitor of NOS1 (N-PLA) abolished the enhancement of the Ca 2+ -regulated exocytotic events stimulated by GW7647 plus ACh, but not an inhibitor of NOS3 (28) . This indicates that NO is mainly produced by NOS1 in antral mucous cells. AA is known to be a natural ligand for PPARα (7, 12, 13) . In the present study, we used AACOCF 3 , which is a nonmetabolic analogue of AA, and a PLA 2 inhibitor. Therefore, the products of AA cascade, such as prostaglandins, thromboxanes, and leukotrienes, do not activate NOS1 to produce NO, because AACOCF 3 inhibits the endogenous AA production. However, AACOCF 3 phosphorylates NOS1 via PI3K/Akt to produce NO in antral mucous cells. This suggests that AA is a key factor to produce NO in antral mucous cells, although an increase in [Ca 2+ ] i appears to be essential to stimulate AA accumulation via PLA 2 . NO synthesis stimulated by PPARα has already been shown in myocardium (5) and endothelial cells (16, 30) . Activation of PPARγ has also been reported to involve NO synthesis in endothelial cells (18) . AA, which activates PPARs, may be a key substance to produce NO in many cell types, although an increase in [Ca 2+ ] i is essential for AA accumulation via PLA 2 . Fig. 7 shows that the signal pathway following the activation of PPARα in antral mucous cells. AACOCF 3 and GW7647 stimulate PPARα leading to NOS1 phosphorylation via PI3K/Akt phosphorylation. The NOS1 phosphorylated produces NO, which accumulates cGMP. The antral mucous cells have cGMP-dependent PDE2, which degrades cAMP. In the Ca 2+ -regulated exocytosis stimulated by ACh, cGMP enhances the initial phase by accelerating the ATP-dependent priming (increasing the number of releasable granules) in antral mucous cells (19) . Therefore, the inhibition of NO production which inhibits cGMP accumulation decreases the initial phase and produces a delayed, but transient, increase in the late phase in antral mucous cells (dotted line). Rp8BrPETcGMPS (an inhibitor of PKG) also induc- Fig. 7 Schematic diagram of NO production stimulated by PPARα in antral mucous cells. The activation of PPARα induces NOS1 phosphorylation mediated via PI3K/Akt phosphorylation. In the Ca 2+ -regulated exocytosis, NO production stimulated by PPARα plays a key role, because NO stimulates cGMP accumulation. Without NO (no cGMP accumulation), the Ca 2+ -regulated exocytosis consists of a decreased initial phase and a delayed, but transient, increase in the late phase in antral mucous cells (dotted line), because of the accumulation of cAMP in the late phase induced by inhibition of cGMP-dependent PDE2. On the other hand, with NO (cGMP accumulation), the Ca 2+regulated exocytosis consists of an enhanced initial phase and a second slower decrease without any transient increase in the late phase, because of no cAMP accumulation in the late phase induced by the PDE2 (solid line). es the characteristic response in the Ca 2+ -regulated exocytotic events during inhibition of NO production (27) . On the other hand, the activation of NO production enhances the initial phase and induces a second slower decrease in the late phase (no delayed, but transient, increase in the late phase) (solid line) (28) . The decreased frequency of exocytosis in the late phase can maintain the continuous mucin secretion and may protect antral mucous cells from an excessive mucin release.
